These patients may benefit from LAMP2A antagonists, which inhibit tumor proliferation and enhance the efficacy of PD-1 monoclonal antibody treatment by upregulating tumor PD-L1 levels, thus contributing to the synergistic improvement of immunotherapy efficacy. This evidence concerns the gene CD274 and neoplasm.